|
GlaxoSmithKline appoints Andrew Witty CEO designate |
|
|
|
09 Oct 2007 |
The Board of GlaxoSmithKline plc today announced the appointment of Andrew Witty as CEO Designate, GlaxoSmithKline
LONDON, UK | October 8, 2007 | The Board of GlaxoSmithKline plc (“GSK”) (LSE & NYSE: GSK) today announced the appointment of Andrew Witty as CEO Designate, GlaxoSmithKline.
Andrew Witty, currently President, Pharmaceuticals Europe for GlaxoSmithKline, will succeed Dr Jean-Pierre Garnier following his retirement as Chief Executive Officer at the end of May 2008.
Sir Christopher Gent, Chairman, GlaxoSmithKline said: “Andrew’s appointment follows a rigorous selection process by the Board of Directors. The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK. The Board is confident that Andrew will build on JP’s considerable achievements which have positioned GSK as a leader of the pharmaceutical industry.”
JP Garnier said: “Andrew has made many significant contributions to GSK and I am very pleased that he is to be our next CEO. I look forward to working with him during our handover and wish him every success.”
GlaxoSmithKline — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
SOURCE: GSK |
